Universal Stool Bank Patientdirected donor GI IBD IBS GVHD ICI Colitis Potential NonCDI Indications Gupta S Mullish BH and Allegretti JR Am J Gastroenterol 2020 FMT The Evolving Risk Landscape ID: 1040750
Download Presentation The PPT/PDF document "Donor Screening Biologic product versus ..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. Donor ScreeningBiologic product versus DrugUniversal Stool BankPatient-directed donorGIIBD, IBS, GVHD ICI ColitisPotential Non-CDI IndicationsGupta S, Mullish BH, and Allegretti JR. Am J Gastroenterol. 2020. FMT: The Evolving Risk LandscapeRisksRegulatory ConcernsShort Term RisksAspirationBowel perforationGastrointestinal symptomsTheoretical RisksAllergy or anaphylaxisSIBOIBD FlareAutoimmune DiseaseTransmission of non-infectious disease/phenotypeInfectious RisksBacteremia/sepsisMulti-drug resistant organismsShigatoxin-producing E. ColiEnteropathogenic E. ColiBlastocystisCMV/EBVCOVID-19/SARS-CoV-2Future Novel PathogensMDRO DecolonizationLiverHepatic Encephalopathy PSC, Alcohol DependenceMetabolicObesity, NAFLDNeurologicAutism Spectrum Disorders, Parkinson’s